Julia M. Adams

An astrocytic ensemble at vHip-NAc synapses modulates cognitive impairments induced by chronic tetrahydrocannabinol exposure

C. Martín, Javier Sánchez Romero, Julia M. Adams, Nagore Puente et autres

Cannabis is the most widely used illicit drug, particularly during adolescence. Its consumption disrupts glutamate homeostasis and synaptic plasticity in the nucleus accumbens (NAc). Here, we identify a functionally distinct accumbal astrocytic ensemble, associated with the ventral hippocampus–NAc (vHip→NAc) circuit, that is …

es, us, fr (code pays fourni par la source)

709. RELATIONSHIP BETWEEN ELECTROENCEPHALOGRAPHY-BASED MISMATCH NEGATIVITY AND ANTIPSYCHOTIC TREATMENT RESPONSE IN YOUNG PEOPLE AT CLINICAL HIGH RISK FOR PSYCHOSIS

M de Rozario, E.C. Rowe, Michael Haaf, Julia M. Adams et autres

Abstract Background Antipsychotic medications are often used to treat individuals at clinical high risk for psychosis (CHR-P). However, up to 75% of these individuals will not develop psychotic disorders, nor benefit from such treatments. To optimize treatment, it is important to tailor …

au, de (code pays fourni par la source)

642. A SYSTEMATIC REVIEW OF NEUROIMAGING BIOMARKERS TO PREDICT ANTIPSYCHOTIC TREATMENT RESPONSE

M de Rozario, Julia M. Adams, Elaine Painter, Tahnee L. Bridson et autres

Abstract Background Up to a third of patients with schizophrenia do not experience sufficient improvement of symptoms and functioning on their first two trials of antipsychotic medications. This is concerning as ineffective antipsychotic treatment early in psychotic illness can lead to exacerbations …

au, de (code pays fourni par la source)

498. Relationship Between Electroencephalography-Based Mismatch Negativity and Antipsychotic Treatment Response in Young People at Clinical High Risk for Psychosis

Magdelene De Rozario, Elise Rowe, Moritz Haaf, Julia M. Adams et autres

au, de (code pays fourni par la source)

515. The Association of Evoked Gamma Power and Clinical Outcome in First Episode Psychosis

Elise Rowe, Moritz Haaf, M de Rozario, Julia M. Adams et autres

au, de (code pays fourni par la source)

Leukotriene A4 hydrolase inhibition improves age-related cognitive decline via modulation of synaptic function

Julia M. Adams, Sanket V. Rege, Angela T. Liu, Ninh V. Vu et autres

Leukotrienes, a class of inflammatory bioactive lipids, are well studied in the periphery, but less is known of their importance in the brain. We identified that the enzyme leukotriene A4 hydrolase (LTA4H) is expressed in healthy mouse neurons, and inhibition of LTA4H …

us (code pays fourni par la source)

Molecular and histological correlates of cognitive decline across age in male C57BL/6J mice

Rachel A. Britton, Angela T. Liu, Sanket V. Rege, Julia M. Adams et autres

INTRODUCTION: Increasing age is the number one risk factor for developing cognitive decline and neurodegenerative disease. Aged humans and mice exhibit numerous molecular changes that contribute to a decline in cognitive function and increased risk of developing age-associated diseases. Here, we characterize …

us, au (code pays fourni par la source)

Author response for "Molecular and histological correlates of cognitive decline across age in male C57BL/6J mice"

Rachel A. Britton, Angela T. Liu, Sanket V. Rege, Julia M. Adams et autres

Author response: Superior colliculus drives stimulus-evoked directionally biased saccades and attempted head movements in head-fixed mice

Sebastian H. Zahler, David E. Taylor, Joey Y. Wong, Julia M. Adams et autres

us (code pays fourni par la source)

Overall survival of pediatric patients enrolled on phase 1 oncology trials.

Stuart Cramer, Julia M. Adams, Joseph Gerald Pressey

e21017 Background: There are few effective therapeutic options for many metastatic or recurrent pediatric malignancies. Phase I trials are a critical step in the development of new agents for such cancers. Given that phase I therapy candidates have exhausted known curative options, …

us (code pays fourni par la source)

Physician and Nurse Beliefs of Phase 1 Trials in Pediatric Oncology

Margaux J. Barnes, Joseph Gerald Pressey, Julia M. Adams, Molly A. Hensler et autres

BACKGROUND: In order to improve the survival of children with cancer, novel therapies must be identified. Promising agents are tested in phase 1 trials in order to identify appropriate dosing and describe toxicity in children. The identification and referral of candidate patients …

us (code pays fourni par la source)

Trial of zoledronic acid and interleukin-2 to expand tumoricidal γδ T cells in vivo in patients with refractory neuroblastoma.

Joseph Gerald Pressey, Julia M. Adams, David R. Kelly, Lawrence S. Lamb

TPS10073 Background: CD3+ γδ+ T cells comprise 2 to 5% of the circulating T cells. Vγ9Vδ2+ cells are the dominant circulating γδ T cell and recognize non-peptide phosphoantigens and stress-associated NKG2D ligands expressed on malignant cells. Strategies that incorporate the tumoricidal properties …

us (code pays fourni par la source)